KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
Balance Sheet
Inspect the capital base behind the business.
Assets
$335.38M
FY 2026 · Annual
+33.7% YoYLiabilities
$338.09M
FY 2026 · Annual
+117.6% YoYEquity
-$2.71M
FY 2026 · Annual
Balance Sheet
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.73M | 56.24M | 31.79M | 98.64M | 229.34M |
| Short-term Investments | 135.47M | 93.14M | 178.61M | 89M | 70.87M |
| Net Receivables | 16.81M | 18.64M | 10.87M | 15.14M | 11.3M |
| Inventory | 0 | 0 | 0 | 0 | 3.43M |
| Other Current Assets | 0 | 0 | 0 | 19.21M | 0 |
| Total Current Assets | 193.65M | 172.33M | 225.69M | 241.69M | 320.15M |
| Property, Plant & Equipment (Net) | 10.04M | 10.77M | 9.15M | 1.99M | 12.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 193K | 106K | 567K | 7.09M | 2.37M |
| Total Non-current Assets | 10.23M | 10.88M | 9.71M | 9.08M | 15.23M |
| Total Assets | 203.88M | 183.2M | 235.4M | 250.77M | 335.38M |
| Account Payables | 3.64M | 4.82M | 9.11M | 4.88M | 8.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 11M | 0 |
| Other Current Liabilities | 4.17M | 4.21M | 6.69M | 0 | 36.8M |
| Total Current Liabilities | 11.58M | 15.03M | 22.81M | 45.17M | 57.36M |
| Long-term Debt | 0 | 0 | 0 | 0 | 139.23M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 105.88M | 11.71M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 119.06M |
| Total Non-current Liabilities | 7.21M | 7.15M | 6.02M | 110.21M | 280.73M |
| Total Liabilities | 18.79M | 22.18M | 28.82M | 155.38M | 338.09M |
| Common Stock | 25K | 34K | 42K | 50K | 51K |
| Retained Earnings | (250.18M) | (343.08M) | (469.73M) | (653.17M) | (762.69M) |
| Accumulated OCI | (3.86M) | (3.06M) | (3.49M) | (5.21M) | (7.13M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 185.09M | 161.03M | 206.58M | 95.39M | (2.71M) |
| Total Debt | 8.19M | 8.23M | 7.32M | 6.31M | 151.58M |
| Net Debt | (22.54M) | (48.01M) | (24.47M) | (92.34M) | (77.77M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $229.3M |
| Short-term Investments | $70.9M |
| Receivables | $11.3M |
| Inventory | $3.4M |
| Other Current | $5.2M |
| Total Current Assets | $320.1M |
| PP&E (Net) | $12.9M |
| Other Non-current | $2.4M |
| Total Non-current Assets | $15.2M |
| Total Assets | $335.4M |
Analysis
Selected assets total $335.4M for Latest. The largest visible component is Cash & Equivalents at $229.3M, about 68.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 |
How much cash does KALV have?
KalVista Pharmaceuticals, Inc. (KALV) reported $229.34M in cash and equivalents in fiscal 2026.
How much debt does KALV carry?
KalVista Pharmaceuticals, Inc. (KALV) reported $151.57M of total debt, with net debt of -$77.77M.
Continue the stock analysis
Jump to another research area for this company.